Success Metrics

Clinical Success Rate
100.0%

Based on 3 completed trials

Completion Rate
100%(3/3)
Active Trials
2(29%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_2
3
43%
Ph phase_3
2
29%
Ph phase_1
2
29%

Phase Distribution

2

Early Stage

3

Mid Stage

2

Late Stage

Phase Distribution7 total trials
Phase 1Safety & dosage
2(28.6%)
Phase 2Efficacy & side effects
3(42.9%)
Phase 3Large-scale testing
2(28.6%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

3 of 3 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

2

trials recruiting

Total Trials

7

all time

Status Distribution
Active(2)
Completed(3)
Other(2)

Detailed Status

Completed3
unknown2
Recruiting2

Development Timeline

Analytics

Development Status

Total Trials
7
Active
2
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 12 (28.6%)
Phase 23 (42.9%)
Phase 32 (28.6%)

Trials by Status

unknown229%
recruiting229%
completed343%

Recent Activity

2 active trials
Showing 5 of 7
recruitingphase_1

A First-in-Human Trial of DS3790a in Participants With Hematological Malignancies

NCT07220616
unknownphase_2

Niraparib and Dostarlimab in HRD Solid Tumors

NCT04983745
completedphase_2

Combination of Anti-PD-1 Antibody and Chemotherapy in Metastatic Pancreatic Cancer

NCT03977272
recruitingphase_3

Induction Chemotherapy for Locally Recurrent Rectal Cancer

NCT04389086
completedphase_1

Clopidogrel Aspirin Therapy (CAT) Versus Apixiban Aspirin Therapy (AAT) After Lower Limb Revascularization

NCT04168398
View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT07220616Phase 1

A First-in-Human Trial of DS3790a in Participants With Hematological Malignancies

Recruiting
NCT04983745Phase 2

Niraparib and Dostarlimab in HRD Solid Tumors

Unknown
NCT03977272Phase 2

Combination of Anti-PD-1 Antibody and Chemotherapy in Metastatic Pancreatic Cancer

Completed
NCT04389086Phase 3

Induction Chemotherapy for Locally Recurrent Rectal Cancer

Recruiting
NCT04168398Phase 1

Clopidogrel Aspirin Therapy (CAT) Versus Apixiban Aspirin Therapy (AAT) After Lower Limb Revascularization

Completed
NCT04125693Phase 2

Roll-over Study to Continue Treatment With the Investigational Drug Rogaratinib and to Further Test Its Safety

Completed
NCT04193982Phase 3

An Investigator Initiated Prospective, Four Arms Randomized Comparative Study of Efficacy and Safety of Saroglitazar, Vitamin E and Life Style Modification in Patients With Nonalcoholic Fatty Liver Disease (NAFLD)/ Non-alcoholic Steatohepatitis (NASH)

Unknown

All 7 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
7